Bridge­Bio's AT­TR-CM tri­al odyssey ends with a win, show­ing pos­i­tive mor­tal­i­ty and hos­pi­tal­iza­tion da­ta

Bridge­Bio’s long wait for the fi­nal re­sults of its Phase III tri­al of aco­ramidis is over.

On Mon­day, the biotech said the 30-month read­out of its drug in pa­tients with transthyretin amy­loid car­diomy­opa­thy (AT­TR-CM) was a suc­cess, show­ing im­prove­ments in mor­tal­i­ty, car­dio­vas­cu­lar-re­lat­ed hos­pi­tal­iza­tions, a six-minute walk test and a bio­mark­er of the dis­ease.

The com­pa­ny said that 81% of pa­tients get­ting the drug were alive at 30 months, com­pared with 74% on place­bo. Aco­ramidis al­so cut the rate of hos­pi­tal­iza­tion by 50%. The mor­tal­i­ty ef­fect wasn’t sta­tis­ti­cal­ly sig­nif­i­cant on its own, the com­pa­ny said on a con­fer­ence call Mon­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER